Metraipolis › archive › dc_6418ccfc86fa

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study — Europe PMC PMID:40610896

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/40610896
DOI: 10.1186/s12865-[numero omesso]-9
License (as archived): solo-consultazione
Archived: 2026-10-07T16:21:55.031Z
SHA-256 of the archived text: b5d9be3439a7b41d6769c58fa6f8fef8b705cfb748d2d0da287a32d3bef1504f
Stable URL of this page: https://metraipolis.com/documento/dc_6418ccfc86fa

How to cite

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study — Europe PMC PMID:40610896 — Europe PMC (en), https://europepmc.org/article/MED/40610896 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6418ccfc86fa (Metraipolis archive dc_6418ccfc86fa, sha256 b5d9be3439a7b41d6769c58fa6f8fef8b705cfb748d2d0da287a32d3bef1504f)

BibTeX

@misc{dc6418ccfc86fa,
  title = {Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study — Europe PMC PMID:40610896},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40610896},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6418ccfc86fa; sha256 b5d9be3439a7b41d6769c58fa6f8fef8b705cfb748d2d0da287a32d3bef1504f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40610896. Agents can read the archived copy with the MCP tool read_document.